The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Intervacc presents to the capital market on three occasions in March
Intervacc AB (publ) is a Swedish biotechnology company developing breakthrough vaccines based on recombinant protein fusions. In March, the company will present at the DNB/Carnegie Healthcare Seminar, Stora Aktiedagarna and Stockholm Corporate Finance Life Science...Article on Intervacc’s Streptococcus suis study published in the journal Vaccine
The scientific journal Vaccine has published an article entitled “Sow vaccination with a novel recombinant protein vaccine protects piglets against Streptococcus suis infection” (DOI: 10.1016/j.vaccine.2025.127077), authored by a research team affiliated...Intervacc has presented new findings at the ACVIM Forum in the United States
Stockholm, June 13th, 2024 – Intervacc AB (publ) has presented new reports highlighting the importance of vaccination to disease control strategies and the safety and efficacy of Strangvac® in the field at the American College of Veterinary Internal Medicine (ACVIM)...Invitation to conference call with presentation of Intervacc’s Interim report for the third quarter, 2023
Stockholm, November 15, 2023 – On Thursday, November 16, 2023 at 08.30 a.m. (CET) Intervacc AB (publ) will publish the Interim report Q3 (July-September), 2023. Following the report’s publication, Intervacc will arrange a conference call. CEO Jonas Sohlman and Chief...Nyhetstjänster
